EC approves dosing flexibility for Novartis’s Cosentyx in psoriatic arthritis treatment

The European Commission (EC) has granted Novartis approval for a significant update to the label of its psoriatic arthritis treatment, Cosentyx (secukinumab). This update introduces ... Read More